Заключение

B будущем эффекты плацебо должны изучаться как в нейроисследованиях, так и в клинической практике и социальной психологии. Использование нового экспериментального дизайна и технологий позволит четко определить отношения между сложной умственной деятельностью (например, ожиданием) и различными нейрональными системами.

Списоклитературы

1. Лапин, И. П. Плацебо и терапия. Серия «Мир медицины». - СПб.: Издательство «Лань», 2000. Стр. 46-49.

2. Amanzio, M. & Benedetti, F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific sub- systems.J. Neurosci. 19:484-494 (1999).

3. Benedetti, F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain. 64:535-543 (1996).

4. Benedetti, F. Cholecystokinin type-A and type-B receptors and their modulation of opioid analgesia. News Physiol Sci. 12:263-268 (1997).

5. Benedetti, F., et al.

6. Benedetti, F., et al. Conscious expectation and unconscious conditioning in analgesic, motor, and

7. hormonal placebo/nocebo responses.J. Neurosci. 23:4315-43 23 (2003).

8. Benedetti, F., Amanzio, M. The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin. Prog Neurobiol. 52:109-125 (1997).

9. Benedetti₁ F., Amanzio₁ M.. Casadio₁ C₁ et al. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain 71:135-140 (1997).

10. Benedetti,F.,Amanzio,M. & Maggi,G.Potentiationofplaceboanalgesia byproglumide. Lancet. 346:1231 (1995).

11. Benedetti₁ F., Amanzio₁ M., Baldi₁ S., Casadio₁ C. & Maggi₁ G. Inducing placebo respiratory depressant responses in humans via opioid receptors. EurJ. Neurosci. 11:625-631 (1999).

12. Benedetti₁ F., Pollo₁ A., Lopiano₁ L₁ Lanotte₁ M., Vighetti₁ S., Rainero₁ I. Conscious expectation and unconscious conditioning in analgesic, motor and hormonal placebo/ nocebo responses.J Neurosci. 23:4315-23 (2003).

13. Benson₁ H., Epstein₁ M. D. The placebo effect. A neglected asset in the care of patient //JAMA.V. 232:1225-1227 (1975).

14. Bingel₁ U., Lorenz₁ J., Schoell₁ E., Weiller₁ C₁ Buchel₁ C. Mechanisms of placebo analgesia: rACC recruitment of subcortical antinociceptive network. Pain. 120(1- 2):8-15(2006).

15. Bromm₁ B.,Jahnke, M.T.,Treede, R. D. Responses of human cutaneous afferents to C02 laser stimuli causing pain. Exp Brain Res. 55:158-66 (1984).

16. Bromm₁ B.. Treede₁ R. D. Nerve fiber discharges, cerebral potentials and sensations induced by C02 laser stimulation.

17. Bromm₁ B., Scharein E., Vahle-Hinz₁ C. Cortex areas involved in the processing of normal and alters pain. Prog Brain Res. 129:289-302 (2000).

18. Colloca₁ L₁ Benedetti₁ F. Placebo and painkillers: is mind as real as matter? Nat Rev Neurosci. 6(7):245-52 (2005).

19. Colloca₁ L₁ Benedetti₁ F. How prior experience shapes placebo analgesia. Pain. 124:126-33 (2006).

20. Colloca₁ L₁ Benedetti₁ F. Nocebo hyperalgesia: how anxiety is turned into pain. Curr Opin An. 20:435-439 (2007).

21. Colloca₁ L., Sigaudo₁ M., Benedetti₁ F. The role of learning on nocebo and placebo effects. Pain. 136:211-8 (2008).

22. Colloca₁ L., Tinazzi₁ M., Recchia₁ S., Le Pera₁ D., Fiaschi₁ A., Benedetti₁ F., Valeriani₁ M. Learning potentiates neurophysiological and behavioral placebo analgesic responses. Pain, doi:10.1016 —1021(2008).

23. Fields, H. L & Price₁ D. D. The placebo Effect: an Interdisciplinary Exploration (ed. Harrington,A.) 93-116 (Harvard Univ. Press₁ Cambridge, Massachusetts, USA₁1997).

24. Fields, H. L & Basbaum,A. I.Textbook of Pain (eds.Wall, P. D. & Melzack₁ R.) 309-329 (Churchill Livingstone, Edinburgh, UK₁1999).

25. Frot₁ M., Rambaud₁ L., Guenot₁ M., Mauguie re₁ F. Intracortical recordings of early pain- related C02-laser evoked potentials in the humansecond somatosensory (SII) area. Clin Neurophysiol. 110:133-45 (1999).

26. Garcia-Larrea₁ L., Frot₁ M., Valeriani₁ M. Brain generators of laserevoked potentials: from dipoles to functional significance. Neurophysiol Clin. 33:279-92 (2003).

27. Gracely₁ R. H.. Dubner₁ R., Wolskee₁ P.

28. Grevert₁ R₁ Albert, L H. & Goldstein₁ A. Partial antagonism of placebo analgesia by naloxone. Pain. 16:129-143 (1983).

29. Hebb₁ A. L. 0., Poulin₁ J-F., Roach₁ S. R₁ et al. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Prog Neuropsychopharmacol Biol Psychiatry. 29:1225-1238 (2005).

30. Heinricher₁ M. M., McGaraughty₁ S.,Tortorici,V. Circuitry underlying antiopioid actions ofcholecystokinin within the rostralventromedial medulla.J NeurophysioL 85:280- 286 (2001).

31. Heinricher₁ M. M., Neubert, Μ. J. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla.J Neurophysiol. 92:1982-1989 (2004).

32. Jones,A. K.,Watabe,H.,Cunningham,V.J.,Jones,T.Cerebraldecreasesinopioid receptor binding in patients with central neuropathic pain measured by [llC] diprenorphine binding and PET. EurJ Pain. 8:479-485 (2004).

33. Jones,A.K.,Cunningham,V.J.,Ha-Kawa,S.,Fujiwara,T.,Luthra,S.K.,Silva,S.,Derbyshire, S.,Jones,T. Changes in central opioid receptor binding in relation to inXammation and pain in patients with rheumatoid arthritis. BrJ Rheumatol. 33:909-16 (1994).

34. Keltner, J. R., Furst₁ A., Fan₁ C₁ et al. Isolating the modulatory effect of expectation on pain transmission: a functional magnetic resonance imaging study. J Neurosci. 26:4437-4443 (2006).

35. Kirsch₁1. Conditioning, expectancy and placebo effect: comment on Stewart-Williams and Podd. Psychol Bull. 2004;130:341-3(2004).

36. Kirsch₁1., Lynn₁ S. J., Vigorito₁ M.. Miller₁ R. R. The role of conditioning in classical and operant conditioning.J Clin Psychol. 60:369-92 (2004).

37. Koyama₁ T₁ McHaffie₁ J. G., Laurienti₁ P. J., Coghill₁ R. C. The subjective experience of pain: where expectations become reality. Proc Natl Acad Sci U S A. 102:12950- 12955 (2005).

38. Leeuw₁ M., Goossens₁ M. E., Linton₁ S. J., et al. The fear-avoidance model of musculoskeletal pain: current state of scientific evidence. J Behav Med. 30:77-94 (2007).

39. Lenz₁ F. A., Rios₁ M., Chau₁ D., Krauss₁ G. L₁ Zirh₁ T A., Lesser₁ R. P. Painful stimuli evoke potentials recorded over th^human anterior cingulated gyrus.J NeurophysioL 79:2231-4 (1998).

40. leuchter, A. F., Cook₁ I. A., Witte₁ E. A., Morgan₁ M. & Abrams₁ M. Changes in brain function of depressed subjects during treatment with placebo. Am. J. Psychiatry. 159:122-129 (2002).

41. Leuchter₁ A. F., et al. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology. 177:15-22 (2004).

42. Levine₁ J. D. & Gordon, N. C. Influence of the method of drug administration on analgesic response. Nature. 312:755-756 (1984).

43. Levine,J. D.,Gordon, N. C. & Fields₁ H. L The mechanisms of placebo analgesia. Lancet. 2:654-657 (1978).

44. Lieberman₁ M. D., et al. The neural correlates of placebo effects: a disruption account. Neuroimage. 22:447-455 (2004).

45. Lipman,J.J., et al. Peak B endorphin concentration in cerebrospinal fluid: reduced in chronic pain patients and increased during the placebo response. Psychopharmacology. 102:112-116 (1990).

46. Lorenz₁ J., Hauck₁ M., Paur₁ R. C., et al. Cortical correlates of false expectations during pain intensity judgments - a possible manifestation of placebo/nocebo cognitions.

47. Matre₁ D., Casey₁ K. L₁ KnardahL S. Placebo-induced changes in spinal cord pain processing.J Neurosci. 26(2):559-563 (2006).

48. Mayberg₁ H. S., et al. The functional neuroanatomy of the placebo effect. Am. J. Psychiatry. 159:728-737 (2002).

49. Mitchel₁ J. M., Lowe₁ D., Fields₁ H. L The contribution of the rostral ventromedial medulla to the antinociceptive effects of systemic morphine in restrained and unrestrained rats. Neuroscience. 87:123-133 (1998).

50. Montgomery, G. H., Kirsch₁ I. Classical conditioning and the placebo effect. Pain. 72:107-13 (1997).

51. Oftedal₁ G., Straume,A.,Johnsson,A.. Stovner₁ L J. Mobile phone headache: a double blind,sham-controlled provocation study. Cephalalgia. 27:447-455 (2007).

52. Petrovic₁ P., Kalso₁ E., Petersson₁ K. M. & Ingvar₁ M. Placebo and opioid analgesia - imaging a shared neuronal network. Science. 295:1737-17 40 (2002).

53. Petrovic₁ P. Opioid and placebo analgesia share the same network. Sem. Pain. Med. 3:31-36 (2005).

54. Ploghaus₁ A., Tracey₁1., Gati₁ J. S.. et aL Dissociating pain from its anticipation in the human brain. Science. 284:1979-1981 (1999).

55. Pollo₁ A.. et al. Response expectancies in placebo analgesia and their clinical relevance. Pain. 93:77-84 (2001).

56. Pollo₁A., Rainero₁ l.,Vighetti, S. & Benedetti₁ F. Placebo analgesia and the heart. Pain. 102:125-133 (2003).

57. Porro₁ C. A., Baraldi₁ R₁ Pagnoni₁ G., et al. Does anticipation of pain affect cortical nociceptive systems?J Neurosci. 22:3206-3214 (2002).

58. Price, D. D. (ed.) Psychological Mechanisms of Pain and Analgesia (IASR Seattle, Washington, USA₁1999).

59. Price₁ D. D.. Craggs₁ J., Nicholas Verne₁ G., et al. Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients. Pain. 127:63-72 (2007).

60. Price₁ D. D.. Milling, L S., Kirsch₁1., Duff,A., Montgomery G. H., NicholU₁ S. S. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain. 83:147-56 (1999).

61. Sawamoto₁ N., Honda₁ M., Okada₁ T₁ et al. Expectation of pain enhances responses to nonpainful somatosensory stimulation in the anterior cingulated cortex and parietal operculum/posterior insula: an event-related functional magnetic resonance imaging study.i Neurosci. 20:7438-7445 (2000).

62. Shapiro₁ A. Placebogenesis and iatroplacebogenesis // Medical Times. V. 92. 1037- 1047 (1964).

63. Shapiro₁ A. Psychochemotherapy // Biological Foundations of Psychiatry / Ed. R. G. Grenell₁ S. Gabay N. Y.: Raven Press₁793-835(1976).

64. Shapiro₁ A. The placebo effect. Principles of Psychopharmacology N. Y.: Academic Press₁441-459 (1978).

65. Tarkka₁ I. M., Treede₁ R. D. Equivalent electrical source analysis of pain-related somatosensory evoked potentiaU elicited by a C02 laser. J Clin Neurophysiol. 10:513-9 (1993).

66. Valeriani₁ M., Rambaud₁ L₁ Mauguie re₁ F. Scalp topography and dipolar source modeling of potentiaU evoked by C02 laser stimulation of the hand. Electroenceph Clin Neurophysiol. 100:343-53 (1996).

67. Vlaeyen₁ J. W., Linton₁ S. J. Fear-avoidance and its consequences in chronic musculoskeletal pain:a state ofthe art. Pain. 85:317-332 (2000).

68. Vogt₁ B. A., Sikes₁ R. W. & Vogt₁ L. J. Neurobiology of Cingulate Cortex and Limbic Thalamus(eds.Vogt, B.A. & Gabriel₁M.) 313-344 (Birkhauser,Boston,Massachusetts. USA₁1993).

69. Voudouris₁ N. J., Peck₁ C. L₁ Coleman₁ G. Conditioned placeboresponses. J Pers Soc Psychol. 48:47-53 (1985).

70. Voudouris₁ N. J., Peck₁ C. L₁ Coleman₁ G. Conditioned response models of placebo phenomena: further support. Pain 38:109-16 (1989).

71. Voudouris₁ N. J., Peck₁ C. L₁ Coleman₁ G. The role of conditioning and verbal expectancy in the placebo response. Pain. 43:121-8 (1990).

72. Wager₁T D.,etal. Placebo-induced changes in fMRI inthe anticipation and experience of pain. Science. 303:116- 127 (2004).

73. Wager, T. D. The neural basis of placebo effects in anticipation and pain. Sem. Pain Med. 3:22-30 (2005).

74. Wager₁ T. D., Matre, D., Casey, K. L Placebo effects in laser-evoked pain potentials. Brain Behav lmmun. 20(3):219-30 (2006).

75. Watson, A.. El-Dereby, W., Vogt, B. A., Jones, A. K. Placebo analgesia is not due to compliance or habituation: EEG and behavioural evidence. Neuroreport. 18:771-5 (2007).

76. Williams-Stewart, S., Podd, J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol BulL 130:324-40 (2004).

77. Willoch, F., et al. Central pain after pontine infarction is associated with changes in opioid receptor binding: a PET study with llC-diprenorphine. Am. J. Neuroradiol. 20:686-690 (1999).

78. Willoch, F., et al. Central poststroke pain and reduced opioid receptor binding within pain processing circuitries: a [llC]dinorphine PET study. Pain. 108:213-220 (2004).

79. Zubieta, J. K., et al. Regional mu opioid receptor regulation of sensory and affective dimension of pain. Science. 293:311-315 (2001).

80. Zubieta, J. K., et al. COMT vall58met genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science. 299:1240-1243 (2003).

81. Zubieta,J. K.,Bueller,J.A.,Jackson,L.R.,etaL Placebo effects mediated byendogenous opioid activity on m-opioid receptors.J Neurosci. 25:7754-7762 (2005).

82. Zubieta, J. K.. Yau₁ W. Y., Scott, D. J., Stolher, C. S. Belief or need? Accounting for individual variations in the neurochemistry of the placebo eVect. Brain Behav lmmun. 20:15-26(2006).

4.4.